APOL5

Across TCGA pan-cancer cohorts, APOL5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated APOL5 data layer compared with 29 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher APOL5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated APOL5 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

KIRC, COAD, and UCEC are the cancer types where APOL5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.123	0.805	<.001	42	view →
COAD	OS	Median	III,IV	0.224	0.798	<.001	21	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LGG	DFS	Median	All	0.249	0.728	.038	3	view →
BLCA	OS	Median	II,III,IV	1.000	0.410	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

APOL5–KIRC (OS)

Open the KIRC breakdown →